Scutellarin (Synonyms: Scutellarein 7-O-β-D-glucuronide) |
Catalog No.GN10624
One-Click Copy Product Info
|
Scutellarin is a flavonoid with multiple biological activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 27740-01-8
Sample solution is provided at 25 µL, 10mM.
Scutellarin is a flavonoid with multiple biological activities[1]. Scutellarin can prevent endothelial dysfunction and prevent atherosclerosis through antioxidant activity[2]. Scutellarin has anti-HIV-1IIIB, HIV-1(74V) and HIV-1KM018 activities with EC50 of 26μM, 253μM and 136μM, respectively[3].
In vitro, Scutellarin (0-210μM) treated human renal cancer cells (ACHN and 786-O cells) for 24-72h inhibited cell proliferation in a dose- and time-dependent manner, induced cell apoptosis and cell cycle arrest at the G0/G1 phase, and increased the expression of phosphatase and tensin homolog (PTEN)[4]. Scutellarin (50μM) pre-treated BV-2 cells for 30min inhibited the production of NO, TNFα, IL-1β and ROS induced by lipopolysaccharide (LPS), and inhibited LPS-induced nuclear translocation and DNA binding activity of nuclear factor κB (NF-κB)[5].
In vivo, Scutellarin (30, 60mg/kg/day) was orally treated for 3 weeks in mice with H1975-Luciferase cell xenografts, which significantly inhibited the growth of transplanted tumors in mice, upregulated the levels of LC3-II and p-ERK1/2 in mouse lung tissue, and downregulated the level of p-AKT[6]. Scutellarin (5mg/kg) was intravenously injected to treat doxorubicin (DOX)-induced cardiac toxicity in rats, significantly reducing serum lactate dehydrogenase (LDH) activity, lipid peroxide (MDA) levels, and cardiac troponin T (cTnT) concentrations, and significantly reducing cardiac tissue damage[7].
References:
[1] Wang Z L, Wang S, Kuang Y, et al. A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis[J]. Pharmaceutical biology, 2018, 56(1): 465-484.
[2] Mo J, Yang R, Li F, et al. Scutellarin protects against vascular endothelial dysfunction and prevents atherosclerosis via antioxidation[J]. Phytomedicine, 2018, 42: 66-74.
[3] Zhang G H, Wang Q, Chen J J, et al. The anti-HIV-1 effect of scutellarin[J]. Biochemical and Biophysical Research Communications, 2005, 334(3): 812-816.
[4] Deng W, Han W, Fan T, et al. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN[J]. Biomedicine & Pharmacotherapy, 2018, 107: 1505-1513.
[5] Wang S, Wang H, Guo H, et al. Neuroprotection of Scutellarin is mediated by inhibition of microglial inflammatory activation[J]. Neuroscience, 2011, 185: 150-160.
[6] Sun C Y, Li C Y, Li X F, et al. Scutellarin induces apoptosis and autophagy in NSCLC cells through ERK1/2 and AKT Signaling Pathways in vitro and in vivo[J]. Journal of Cancer, 2018, 9(18): 3247.
[7] Sun X P, Wan L L, Yang Q J, et al. Scutellarin protects against doxorubicin-induced acute cardiotoxicity and regulates its accumulation in the heart[J]. Archives of pharmacal research, 2017, 40: 875-883.
| Cell experiment []: | |
Cell lines | ACHN、786-O cells |
Preparation Method | ACHN and 786-O cells were seeded into 96-well plates at the concentration of 5×103 cells per well and cultured to 70–80% confluence, cells were treated with different concentrations (0, 30, 60, 90, 120, 150, 180, and 210μM) of Scutellarin dissolved in DMSO for 24, 48, 72h at the indicated time point, 10μl of CCK-8 solution was added into each well and incubated for 2h. |
Reaction Conditions | 0, 30, 60, 90, 120, 150, 180, 210μM; 24, 48, 72h |
Applications | Scutellarin inhibites cell proliferation in dose- and time- dependent manner. |
| Animal experiment []: | |
Animal models | BALB/c nude mice |
Preparation Method | Mice were subcutaneously injected with 4×106 H1975-Luciferase cells (stably expressing fluorescence). When tumor reached approximately 100mm3, mice were randomly divided into three groups (n=8): the vehicle; the low dose Scutellarin (30mg/kg); the high dose Scutellarin (60mg/kg). At this point, Scutellarin was dissolved in PBS, and was orally administered to each mouse once a day for three weeks. The tumor dimensions were measured using digital calliper every 3 days. Before treatment or after the last administration, the tumor size was monitored by in vivo bioluminescence imaging. After 3 weeks, all mice were humanely sacrificed and the tumors were resected for protein quantitation analysis. |
Dosage form | 30, 60mg/kg/day for 3 weeks; p.o. |
Applications | Scutellarin suppressed tumor growth in mouse xenograft model. Scutellarin treatment could up-regulate LC3-II and p-ERK1/2 level, and down-regulate p-AKT. |
References: | |
| Cas No. | 27740-01-8 | SDF | |
| Synonyms | Scutellarein 7-O-β-D-glucuronide | ||
| Chemical Name | (2S,3S,4S,5R,6S)-6-[5,6-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-7-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid | ||
| Canonical SMILES | C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O | ||
| Formula | C21H18O12 | M.Wt | 462.37 |
| Solubility | ≥ 46.2mg/mL in DMSO | Storage | Store at 2-8°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1628 mL | 10.8139 mL | 21.6277 mL |
| 5 mM | 432.6 μL | 2.1628 mL | 4.3255 mL |
| 10 mM | 216.3 μL | 1.0814 mL | 2.1628 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)